Danam signs merger agreement with Artemis
2023-08-08
并购高管变更
Preview
来源: Pharmaceutical Technology
Danam will focus on expanding its health ecosystem model to further patient care and boost coordination among healthcare providers. Credit: michaeljung / Shutterstock.com.
Health services technology and pharmaceutical distribution company Danam Health has signed a merger deal with publicly traded special purpose acquisition company Artemis Strategic Investment.
ASIC Merger Sub, a newly created subsidiary of Artemis, will be merged into Danam as part of the deal.
Recommended Reports
Preview
来源: Pharmaceutical Technology
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Ramelteon in Delirium GlobalData
View allCompanies IntelligenceArtemis Strategic Investment CorpDanam HealthArtemis S.A.DAN-AM COView all
The merged business will be known as Danam Health Holdings Corporation and will have a pro forma equity value of $200m.
Artemis will support Danam by offering access to key markets and expediting the development of its health ecosystem model.
This approach will facilitate the closure of a crucial gap in the last-patient delivery of healthcare services.
Following the merger, Danam will focus on expanding its health ecosystem model to further patient care aspects such as remote patient monitoring and boosting care coordination among various healthcare providers.
The boards of directors of Danam and Artemis granted unanimous approval for the deal.
Danam CEO Suren Ajjarapu will become CEO and chairman of the board of directors of the combined company.
Ajjarapu stated: “The healthcare industry has seen rising costs, including $378bn spent on prescription drugs in 2021 alone.
“At Danam, we will focus on lowering these costs while improving medication adherence and promoting favourable outcomes in patient care.
“Our advanced technology solutions will aid consumers with taking control of their health by equipping them with convenient access to prescription and health services through our technology platform and applications.”
The merger will conclude in the fourth quarter of 2023.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-药物
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。